Biocon (BIOCON) | Financial Analysis & Statements
Biocon Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
39.1B
Gross Profit
25.0B
64.06%
Operating Income
2.9B
7.52%
Net Income
892.0M
2.28%
EPS (Diluted)
₹0.26
Balance Sheet Metrics
Total Assets
588.0B
Total Liabilities
310.8B
Shareholders Equity
277.1B
Debt to Equity
1.12
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Biocon Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 150.5B | 142.0B | 109.3B | 80.2B | 70.1B |
| Cost of Goods Sold | 52.0B | 49.1B | 36.7B | 27.2B | 22.5B |
| Gross Profit | 98.5B | 92.9B | 72.7B | 53.0B | 47.6B |
| Gross Margin % | 65.5% | 65.4% | 66.5% | 66.1% | 68.0% |
| Operating Expenses | |||||
| Research & Development | 6.3B | 8.0B | 8.8B | 3.1B | 5.3B |
| Selling, General & Administrative | 12.7B | 8.9B | 4.9B | 4.3B | 4.9B |
| Other Operating Expenses | 16.6B | 22.1B | 15.9B | 9.4B | 8.0B |
| Total Operating Expenses | 35.6B | 38.9B | 29.6B | 16.8B | 18.2B |
| Operating Income | 16.3B | 13.5B | 12.3B | 10.7B | 6.0B |
| Operating Margin % | 10.8% | 9.5% | 11.3% | 13.3% | 8.6% |
| Non-Operating Items | |||||
| Interest Income | 1.1B | 1.6B | 1.1B | 1.1B | 770.0M |
| Interest Expense | 8.9B | 9.7B | 4.2B | 676.0M | 577.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 18.9B | 15.3B | 9.0B | 9.8B | 10.7B |
| Income Tax | 4.6B | 2.3B | 2.5B | 2.1B | 2.2B |
| Effective Tax Rate % | 24.2% | 14.9% | 28.3% | 21.5% | 20.7% |
| Net Income | 14.3B | 13.0B | 6.4B | 7.7B | 8.5B |
| Net Margin % | 9.5% | 9.1% | 5.9% | 9.6% | 12.1% |
| Key Metrics | |||||
| EBITDA | 33.6B | 30.3B | 25.3B | 19.6B | 16.7B |
| EPS (Basic) | ₹8.46 | ₹8.55 | ₹3.88 | ₹5.44 | ₹6.24 |
| EPS (Diluted) | ₹8.46 | ₹8.54 | ₹3.87 | ₹5.42 | ₹6.19 |
| Basic Shares Outstanding | 1197455499 | 1195428813 | 1193095945 | 1191074681 | 1187130762 |
| Diluted Shares Outstanding | 1197455499 | 1195428813 | 1193095945 | 1191074681 | 1187130762 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Biocon Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 32.3B | 12.3B | 13.2B | 6.6B | 9.5B |
| Short-term Investments | 17.0B | 18.8B | 24.0B | 13.4B | 16.9B |
| Accounts Receivable | 54.9B | 62.3B | 35.7B | 20.6B | 15.0B |
| Inventory | 49.3B | 49.4B | 42.4B | 23.0B | 18.7B |
| Other Current Assets | 7.5B | 7.2B | 5.9B | 4.2B | 3.6B |
| Total Current Assets | 162.9B | 151.8B | 123.3B | 83.8B | 76.0B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 4.3B | 4.3B | 3.9B | 3.5B | 3.5B |
| Goodwill | 438.4B | 430.3B | 428.0B | 13.4B | 12.3B |
| Intangible Assets | 102.7B | 102.9B | 105.3B | 12.9B | 11.7B |
| Long-term Investments | 1.9B | 2.7B | 1.5B | 1.5B | 656.0M |
| Other Non-Current Assets | 4.8B | 4.3B | 1.0M | 1.6B | 1.8B |
| Total Non-Current Assets | 425.1B | 408.9B | 397.1B | 120.1B | 109.2B |
| Total Assets | 588.0B | 560.7B | 520.4B | 203.9B | 185.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 65.5B | 62.7B | 38.4B | 16.1B | 15.1B |
| Short-term Debt | 54.2B | 28.5B | 25.2B | 9.3B | 14.1B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 370.0M | 27.8B | 2.3B | 320.0M | 293.0M |
| Total Current Liabilities | 143.3B | 153.6B | 85.1B | 38.3B | 42.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 129.4B | 134.2B | 155.0B | 42.2B | 30.8B |
| Deferred Tax Liabilities | 3.6B | 3.9B | 3.8B | 523.0M | 323.0M |
| Other Non-Current Liabilities | 5.1B | 3.1B | 25.6B | 12.2B | 10.3B |
| Total Non-Current Liabilities | 167.5B | 154.4B | 210.4B | 71.0B | 58.0B |
| Total Liabilities | 310.8B | 308.0B | 295.5B | 109.2B | 100.1B |
| Equity | |||||
| Common Stock | 6.0B | 6.0B | 6.0B | 6.0B | 6.0B |
| Retained Earnings | 189.6B | 176.0B | 160.9B | 68.3B | 62.4B |
| Treasury Stock | 784.0M | 971.0M | 971.0M | 324.0M | 1.3B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 277.1B | 252.7B | 224.9B | 94.7B | 85.1B |
| Key Metrics | |||||
| Total Debt | 183.6B | 162.8B | 180.2B | 51.5B | 44.8B |
| Working Capital | 19.5B | -1.8B | 38.2B | 45.5B | 33.9B |
Balance Sheet Composition
Biocon Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 14.3B | 13.0B | 6.4B | 7.7B | 8.5B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 1.4B | 1.0B | 1.4B | 1.3B | 1.1B |
| Working Capital Changes | 3.4B | -35.7B | 32.3B | -9.5B | -7.3B |
| Operating Cash Flow | 17.8B | -7.5B | 43.7B | 231.0M | 1.9B |
| Investing Activities | |||||
| Capital Expenditures | -21.4B | -16.6B | -15.9B | -17.0B | -15.1B |
| Acquisitions | 18.3B | -5.5B | -122.2B | 0 | -1.0B |
| Investment Purchases | -102.4B | -53.3B | -187.1B | -77.9B | -97.0B |
| Investment Sales | 104.1B | 66.5B | 182.5B | 80.2B | 78.5B |
| Investing Cash Flow | -1.4B | -9.0B | -142.7B | -14.6B | -35.6B |
| Financing Activities | |||||
| Share Repurchases | - | 0 | -647.0M | -3.0M | -93.0M |
| Dividends Paid | -829.0M | -2.0B | -718.0M | - | - |
| Debt Issuance | 96.6B | 13.7B | 109.4B | 10.7B | 26.6B |
| Debt Repayment | -97.7B | -27.7B | -281.0M | -10.9B | -7.3B |
| Financing Cash Flow | -10.8B | -14.4B | 135.5B | 3.6B | 26.9B |
| Free Cash Flow | 17.2B | 10.2B | 1.3B | -7.5B | -5.9B |
| Net Change in Cash | 5.5B | -30.9B | 36.4B | -10.8B | -6.9B |
Cash Flow Trend
Biocon Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
71.84
Forward P/E
38.56
Price to Book
1.68
Price to Sales
3.37
PEG Ratio
0.17
Profitability Ratios
Profit Margin
3.59%
Operating Margin
7.63%
Return on Equity
3.66%
Return on Assets
1.72%
Financial Health
Current Ratio
1.16
Debt to Equity
50.02
Beta
0.25
Per Share Data
EPS (TTM)
₹4.87
Book Value per Share
₹207.92
Revenue per Share
₹132.59
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| BIOCON | 566.5B | 71.84 | 1.68 | 3.66% | 3.59% | 50.02 |
| OneSource Specialty | 202.8B | 936.63 | 3.11 | -0.31% | 1.42% | 21.93 |
| Concord Biotech | 106.3B | 34.14 | 5.86 | 20.50% | 26.97% | 0.09 |
| Blue Jet Healthcare | 70.0B | 23.87 | 5.56 | 26.93% | 27.88% | 1.64 |
| Supriya Lifescience | 51.7B | 27.94 | 4.78 | 18.86% | 25.19% | 0.48 |
| Zota Health Care | 39.4B | -62.53 | 12.61 | -24.83% | -15.37% | 56.90 |
Financial data is updated regularly. All figures are in the company's reporting currency.





